Antengene在2025年研发日分享了有希望的癌症药物临床结果,强调反应率和安全性很强。 Antengene shared promising clinical results for its cancer drugs at its 2025 R&D Day, highlighting strong response rates and safety.

Antengene Corporation于11月20日举办2025研发日活动, 提供几个中晚阶段的最新临床数据。 Antengene Corporation held its 2025 R&D Day on November 20, presenting updated clinical data for several mid- to late-stage programs. ATG-022, aN18.2目标ADC, 显示在中度至高度表达式的病人中,有40%的客观反应率和90%的疾病控制率,具有有利的安全特征。 ATG-022, a CLDN18.2-targeted ADC, showed a 40% objective response rate and 90% disease control rate in patients with moderate to high CLDN18.2 expression, with a favorable safety profile. ATG-037,一种口服CD73抑制剂,在抗CPI的黑瘤和非小细胞肺癌中表现出反应。 ATG-037, an oral CD73 inhibitor, demonstrated responses in CPI-resistant melanoma and non-small cell lung cancer. ATG-101和ATG-125正在临床发展方面取得进展,而Antengene则强调其AnTenGager T细胞接触器平台和在自发免疫疾病方面的临床前期工作。 ATG-101 and ATG-125 are advancing in clinical development, while Antengene highlighted its AnTenGager T-cell engager platform and preclinical work in autoimmune diseases. 这次活动在上海和网上举行,由王新教授作主旨发言。 The event featured a keynote by Prof. Xin Wang and was held in Shanghai and online.